

**Table 1.** General data of patients hospitalized in may for severe COVID-19, by survival group.

	<b>Total (n=171)</b>	<b>Survivors (n=90)</b>	<b>Non-survivors (n=81)</b>	<b>Value p*</b>
	$\mu$ (SD)	$\mu$ (SD)	$\mu$ (SD)	
<b>Age</b> (years)	58 (13.7)	55.8 (14.3)	60.1 (11.8)	0.008
<b>BMI</b> (kg/m <sup>2</sup> )	29.9 (6.1)	29.3 (5.3)	31.1 (7.4)	0.096
	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	<b>p<sup>**</sup></b>
<b>Sex</b>				
Man	123 (71.9)	64 (37.4)	59 (34.5)	0.802
Woman	48 (28.1)	26 (15.2)	22 (12.9)	
<b>Smoking</b>	46 (26.9)	25 (14.6)	21 (12.3)	0.785
<b>Comorbidities</b>				
Hypertension	64 (37 %)	31 (48)	33 (19.3)	0.396
Diabetes	58 (34 %)	28 (48)	30 (17.5)	0.414
COPD/asthma	9 (5 %)	1 (1)	6 (3.5)	0.038
Heart disease	6 (4 %)	5 (5)	2 (1.16)	0.309
CKD	4 (2 %)	3 (3)	1 (.58)	0.364
Cancer	3 (2 %)	3 (3)	1 (.58)	0.364
RA	3 (2 %)	2 (2)	0 (0)	0.177
Venous insufficiency	2 (1 %)	3 (3)	1 (.58)	0.364
Other	7 (4 %)	3 (3)	1 (.58)	0.370
No comorbidity	15 (9%)	0 (0)	15 (8)	--
<b>Symptoms on admission</b>	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	
Fever	106 (62)	72 (42.6)	33 (19)	0.0001
Cough	110 (64)	75 (43.8)	35 (20.2)	0.0001
Dyspnea	103 (60)	81 (47.3)	29 (12.6)	0.01
Myalgia	82 (48)	60 (35.1)	22 (12.9)	0.0001
Headaches	72 (42)	47 (27.4)	25 (14.5)	0.0001
Chest pain	60 (35)	42 (24.5)	18 (10.4)	0.0001
Hyporexia,	50 (30)	33 (19)	17 (10.7)	0.0001
Shivers	31 (18)	12 (7.0)	19 (11)	0.930
Odynophagia	26 (16)	21 (12.2)	5 (3.7)	0.0001
Rhinorrhea	20 (12)	15 (8.7)	5 (3.2)	0.0001
Nausea	219 (11)	12 (7.0)	21 (3.9)	0.034
Diarrhea	20 (12)	16 (9.3)	4 (2.6)	0.009
Abdominal pain	8 (5)	5 (2.9)	3 (2.1)	0.577
Conjunctivitis	6 (3.5)	5 (2.9)	1 (0.6)	0.128
Vomit	5 (3)	4 (2.3)	1 (0.6)	0.218
<b>Pharmacotherapy</b>				
Steroids (methylprednisolone)	73 (57)	58 (33.9)	40 (23.3)	0.047
Antibiotics	167 (97)	90 (52)	78 (45)	0.257

Lopinavir/ritonavir	2 (1.16)	1 (0.6)	1 (0.6)	0.933
Thromboprophylaxis (LMWH)	153 (89)	83 (52.6)	70 (47.4)	0.11

Abbrev.:  $\mu$  = Mean. SD = Standard deviation, n = Frequency \* = t de Student. \*\*= $X^2$ .

COPD: Chronic obstructive pulmonary disease, CKD: chronic kidney disease, RA:

Rheumatoid arthritis. LMWH: Low molecular weight or unfractionated heparin

\* Compared qualitative variables chi-square test and quantitative student's t test

**Table 2.** Assessment scales used in patients with severe COVID-19 infection among surviving and non-survivors patients.

	Total (n= 171)		Survivors (n= 90)		Non-survivors (n=81)		Value
	n	%	n	%	n	%	p*
<b>NEWS</b>							
High risk	53	31	22	12.9	31	18.1	0.273
Moderate risk	69	40.4	39	22.8	30	17.5	
Low risk	44	25.7	26	15.2	18	10.5	
<b>ORBIT</b>							
High bleeding risk	4	2.3	2	1.2	2	1.2	0.779
Risk of intermediate bleeding	6	3.5	4	2.3	2	1.2	
Low risk of bleeding	161	94.2	84	49.1	77	45	
<b>PADUA</b>							
High risk of thrombosis	170	99.3	90	52.6	80	46.5	0.047
Low risk of thrombosis	1	0.7	--	--	1	0.7	
<b>Creatinine clearance</b>							
<30 ml / min / 1,73 m <sup>2</sup>	10	5.8	3	2.1	7	4.9	0.070
>30 ml / min / 1,73 m <sup>2</sup>	133	77.8	79	55.2	54	37.8	
No data	28	16.4	--	--	--	--	

n = Frequency . %= percentage. \* = p value X<sup>2</sup> linear by linear.

**Table 3.** Clinical, biochemical and gasometric values at admission and at 72 hours, average days of care and imaging studies by groups study.

	Total (n=145)	Survivors (n= 88)		Non-survivors (n= 57)		Value p*
	μ (SD)	μ	(SD)	μ	(SD)	
HR (by min)	99 (20.2)	98	19	100	20.8	0.307
RR (by min)	24 (6)	23	6.5	24	5	0.532
MAP (mmHg)	88 (12.8)	88.4	11.7	87.8	14.1	0.734
Temperature (°C)	37.09 (.8)	37.1	.90	37.0	.78	0.834
<b>Initial blood gas</b>						
Oximetry (%)	72 (20)	75.9	22	67	20.9	0.001
FiO2 ingreso (%)	26(18)	21.5	4.9	33.3	17.5	0.005
pH ingreso	7.35 (.4)	7.4	.04	7.1	.86	0.056
PaO2 (mmHg)	60.5 (25.6)	63.8	23	47	11.8	0.226
PaCO2 (mmHg)	29.8 (9.4)	27.6	6	30.7	7.2	0.021
HCO3 (mEq/L)	20.1 (3.9)	21.9	24.7	18.2	3.1	0.315
SaO2 (%)	84.9 (11.7)	88.4	10.6	80	8.6	0.003
PaO2/FiO2 (mmHg:%)	253.2 (116)	297	113	166	64	0.0001
<b>Blood gas analysis at 72 hours</b>						
Oximetry (%)	72.6 (24)	--	--	76.8	17	--
FiO2 (%)	34.6 (24.6)	25.9	15.5	53.4	30	0.0001
pH	7.37 (.1)	7.4	.05	7.2	.05	0.0001
PaO2 (mmHg)	68.2 (10.2)	65.4	16	70	0	0.064
PaCO2 (mmHg)	35.9 (11.9)	31.4	6.9	43.2	14.5	0.0001
HCO3 (mmHg)	20.3 (4.1)	20	3.4	20.7	4.9	0.450
SaO2 (%)	85.6 (13.8)	88.7	6.4	8..8	19.8	0.016
PaO2/FiO2 (mmHg:%)	266 (120)	322	74	163	121	0.0001
<b>Initial hematic biometry</b>						
	Median (range)	Median	Range	Median	Range	p
Leukocytes (mm <sup>3</sup> )	9.6 (3.2–28.9)	8.7	3 -18	11.1	3 -28	0.004**
Lymphocytes (mm <sup>3</sup> )	1.1(.11-4.4)	1.3	.18 – 4.4	.86	.11- 2.24	0.000**
Hemoglobin (g/dl)	14.2(6.6-18.4)	14.2	7.2–18.4	14.2	6.6–18.2	0.725**
Platelets (mm <sup>3</sup> )	265 (50-765)	281	50 -765	240	60-560	0.037**
Albumin (g/dl)	3.0 (1.6-4.3)	3.1	1.6-4.3	2.9	2.3-3.5	0.105**
LDH (UI/L)	847(172-2050)	714	172-1470	1040	298-2050	0.000**
CPK (UI/L)	194 (4-2213)	157	21-1977	250	4.3-2213	0.020**

CPK-MB (ng/ml)	37 (10–1461)	22	10-124	58	10-1461	0.001**
CRP (mg/L)	300(24–520)	314	162-430	281	24-520	0.035**
<b>Hematic biometry at 72 hours</b>						
Leukocytes (mm <sup>3</sup> )	9.6 (2.7-31.1)	7.7	2.7-16.5	13.8	4.1-33.8	0.0001**
Lymphocytes (mm <sup>3</sup> )	1.2 (.19-6.8)	1.4	.19-6.8	.75	.33-3.7	0.0001**
Hemoglobin (g/dl)	13.3 (5.4-17.5)	13.6	6.7-17.5	12.8	5.4-17.5	0.126**
Platelets (mm <sup>3</sup> )	336 (109-674)	362	123-674	282	109-660	0.003**
Albumin (g/dl)	2.8 (1.7-4.0)	2.8	1.7-4.0	2.7	1.7-3.1	0.047**
LDH (UI/L)	773 (259-2248)	606	263-1517	1096	259-2248	0.0001**
CPK (UI/L)	272 (21–3392)	100.7	22-1293	562	21-3392	0.0001**
CPK-MB (ng/ml)	25 (8-77)	19.3	8-50	35	16-77	0.0001**
CRP (mg/L)	136 (.34 -3547)	57	.34-251	280	11-3547	0.0001**
<b>Medium care days</b>						
Ventilation days	4.6 (1-21)	--	--	4.6	1-21	--
Days of pronation	3.6 (1-10)	--	--	3.6	1-10	--
Steroid treatment days	2.9 (0-13)	3.1	0-12	2.5	0-13	0.665**
Antibiotic days	3.7 (1-13)	--	--	3.7	1-13	--
Thromboprophylaxis days	8.1 (1-30)	9.7	2-30	6.0	1-30	0.0001**
Hospital care days	7.9 (1-50)	9.5	2-31	6.0	1-50	0.000**
	<b>n (%)</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>p</b> ***
<b>Imaging studies</b>						
Consolidation	6 (3.5)	5	5.5	1	2	0.125
Opacity in ground glass	85 (49.7)	65	72.2	20	24	0.000
Bilateral lung infiltration	6 (3.5)	6	6.6	0	0	0.017
W/R	74(43.3)	14	15.5	60	74	--

HR: Heart rate, RR: Respiratory rate, MAP: Mean arterial pressure, n= Frequency.  $\mu$ = Mean. SD = Standard deviation. \* = t de Student. \*\* U the Mann-Whitney \*\*\*= $\chi^2$ , LDH= Lactic dehydrogenase, CPK: Creatinine phosphokinase, CRP: C-reactive protein, CPK= Creatin-fosfoquinasa, W/R= without result.

**Table 4.** Univariate and multivariate analysis in patients with severe COVID-19 for the presentation of hospital death with the use of thromboprophylaxis.

	Univariate			Multivariate		
	OR	IC95%	p	HR	IC95%	p
Age > 60 years	2.18	1.18 – 4.02	0.012	8.68	1.88 – 40.0	0.006
Male gender	1.08	0.55 – 2.12	0.802	--	--	--
Smoking	0.91	0.46 – 1.79	0.785	--	--	--
Diabetes	1.30	0.69 – 2.45	0.414	--	--	--
Hypertension	1.30	0.70 – 2.43	0.396	--	--	--
BMI>30	2.27	1.08 – 4.75	0.028	3.8	.602 – 24.2	0.155
MAP	1.13	0.15 – 8.21	0.904	--	--	--
Leukocytes	3.57	1.72 – 7.40	0.000	--	--	--
Lymphocytopenia	3.62	1.78 – 7.38	0.000	.427	0.042 – 4.38	0.474
Anemia	0.67	0.22 – 2.05	0.484	--	--	--
LDH	1.70	1.47 – 1.95	0.404	--	--	--
CPK	2.58	1.14 - 5.82	0.020	.583	.192 – 1.77	--
PaO2/FiO2<300	12.4	3.89 – 39.7	0.000	7.43	1.27 – 43.4	0.026
CRP>200	2.6	1.27 – 5.38	0.008	5.29	1.36 – 20.4	0.016
CKD	3.41	.845 – 13.7	.070	.988	.967 – 1.01	0.272
Steroid	0.53	0.29 – 0.99	0.047	.954	.270 – 3.37	0.942
Thromboprophylaxis	.145	.031 - .674	.005	--	--	--
Thromboprophylaxis Days	0.14	0.03 – 0.67	0.005	.841	.724 - .976	0.023

HR: Hazard ratio. IC95% Confidence interval 95%. p = value p.